Adallen Pharma Limited
Adallen Pharma Limited, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative healthcare solutions. Founded in 2015, the company has rapidly established itself in key operational regions across Europe and beyond, focusing on advanced drug formulations and delivery systems. With a commitment to quality and efficacy, Adallen Pharma offers a range of core products, including prescription medications and over-the-counter solutions that address various health conditions. Their unique approach to research and development has led to several notable achievements, positioning them as a trusted name in the market. As they continue to expand their portfolio, Adallen Pharma remains dedicated to improving patient outcomes through cutting-edge pharmaceutical advancements.
DitchCarbon Score
How does Adallen Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adallen Pharma Limited's score of 29 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adallen Pharma Limited's reported carbon emissions
In 2023, Adallen Pharma Limited reported total carbon emissions of approximately 59,000 kg CO2e, with emissions categorised into Scope 2 and Scope 3. The company recorded 5,000 kg CO2e in Scope 2 emissions, all from purchased electricity. Scope 3 emissions were significantly higher, totalling about 54,000 kg CO2e, which included 1,000 kg CO2e from employee commuting, 20,000 kg CO2e from purchased goods and services, 2,000 kg CO2e from fuel and energy-related activities, 11,000 kg CO2e from upstream transportation and distribution, and 14,000 kg CO2e from downstream transportation and distribution. Currently, Adallen Pharma has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of Scope 1 emissions suggests that the company may not have direct emissions from owned or controlled sources. As the pharmaceutical industry increasingly focuses on sustainability, Adallen Pharma's emissions data highlights the importance of addressing Scope 3 emissions, which often represent the largest share of a company's carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | - |
| Scope 2 | 5,000 |
| Scope 3 | 54,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adallen Pharma Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
